Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Nomogram for visual acuity outcome after iodine-125 plaque radiotherapy and prophylactic intravitreal bevacizumab for uveal melanoma in 1131 patients.

Dalvin LA, Zhang Q, Hamershock RA, Chang M, Yu MD, Mashayekhi A, Shields CL.

Br J Ophthalmol. 2019 Aug 13. pii: bjophthalmol-2019-314686. doi: 10.1136/bjophthalmol-2019-314686. [Epub ahead of print]

PMID:
31409650
2.

CONJUNCTIVAL MYXOID LESIONS: CLINICAL-PATHOLOGIC MULTIPARAMETRIC ANALYSIS, INCLUDING MOLECULAR GENETICS (AN AMERICAN OPHTHALMOLOGICAL SOCIETY THESIS).

Milman T, Salomao DR, Ida CM, Capiz Correa DR, Grossniklaus HE, Zhang Q, Hamershock RA, Shields C, Shields J, Raber I, Rapuano CJ, Patel R, Eagle RC Jr.

Am J Ophthalmol. 2019 May 9. pii: S0002-9394(19)30208-9. doi: 10.1016/j.ajo.2019.04.027. [Epub ahead of print]

PMID:
31078543
3.

Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial.

Chao TF, Chen SA, Ruff CT, Hamershock RA, Mercuri MF, Antman EM, Braunwald E, Giugliano RP.

Eur Heart J. 2019 May 14;40(19):1518-1527. doi: 10.1093/eurheartj/ehy807.

PMID:
30590425
4.

Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial.

Steffel J, Ruff CT, Braunwald E, Hamershock RA, Murphy SA, Nieminen M, Lanz HJ, Mercuri MF, Peterson N, Antman EM, Giugliano RP.

Europace. 2019 Feb 1;21(2):306-312. doi: 10.1093/europace/euy253.

PMID:
30462220
5.

Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial.

Corbalán R, Nicolau JC, López-Sendon J, Garcia-Castillo A, Botero R, Sotomora G, Horna M, Ruff CT, Hamershock RA, Grip LT, Antman EM, Braunwald E, Giugliano RP.

J Am Coll Cardiol. 2018 Sep 25;72(13):1466-1475. doi: 10.1016/j.jacc.2018.07.037.

PMID:
30236308
6.

Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial.

Eisen A, Ruff CT, Braunwald E, Hamershock RA, Lewis BS, Hassager C, Chao TF, Le Heuzey JY, Mercuri M, Rutman H, Antman EM, Giugliano RP.

J Am Heart Assoc. 2017 Jun 30;6(7). pii: e006035. doi: 10.1161/JAHA.117.006035.

7.

Impact of standardized clinical assessment and management plans on resource utilization and costs in children after the arterial switch operation.

Rathod RH, Jurgen B, Hamershock RA, Friedman KG, Marshall AC, Samnaliev M, Graham DA, Jenkins K, Lock JE, Powell AJ.

Congenit Heart Dis. 2017 Dec;12(6):768-776. doi: 10.1111/chd.12508. Epub 2017 Jun 28.

PMID:
28660735
8.

First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trial.

Steffel J, Ruff CT, Hamershock RA, Murphy SA, Senior R, Roy D, Lanz HJ, Mercuri MF, Antman EM, Giugliano RP.

Int J Cardiol. 2017 Oct 1;244:192-195. doi: 10.1016/j.ijcard.2017.05.098. Epub 2017 Jun 2.

PMID:
28625512
9.

Dental students' HIV/AIDS-related knowledge, attitudes, and intentions: impact of the U.S. Health Resources and Services Administration's community-based dental partnership program.

Hamershock RA, Rajabiun S, Fox JE, Mofidi M, Abel SN, York JA, Kunzel C, Sanogo M, Mayfield TG.

J Dent Educ. 2014 Aug;78(8):1106-17.

Supplemental Content

Loading ...
Support Center